ライフサイエンスコーパス: adverse event

1 -101 reported at least one treatment-related adverse event.

2 370 patients had a serious treatment-related adverse event.

3 , and no participants withdrew because of an adverse event.

4 nt with oral morphine, with similar rates of adverse events.

5 perglycemia among the most common high grade adverse events.

6 d in any study, but there were no reports of adverse events.

7 n hemodynamic outcomes, and low incidence of adverse events.

8 rained by reliance on voluntary reporting of adverse events.

9 and 2 discontinued treatment due to serious adverse events.

10 There was no difference in adverse events.

11 dy drugs were well tolerated with no serious adverse events.

12 (n=6; 20%); four patients (13%) had serious adverse events.

13 formulations caused comparable, mainly local adverse events.

14 dentification of persons at risk for serious adverse events.

15 the intervention was high and there were no adverse events.

16 imumab plus methotrexate discontinued due to adverse events.

17 Special care was taken to include all adverse events.

18 t MRI was not associated with an increase in adverse events.

19 ed safety, assessed as the rate and grade of adverse events.

20 Institute's Common Terminology Criteria for Adverse Events.

21 ction is associated with a high rate of late adverse events.

22 idence of neonatal adverse outcomes or other adverse events.

23 ll laborious and carries substantial risk of adverse events.

24 4) being the most common treatment-emergent adverse events.

25 analyses by intention-to-treat and assessed adverse events.

26 Secondary outcomes were adverse events.

27 ed discontinuation of therapy due to serious adverse events.

28 creased risk of complicated appendicitis and adverse events.

29 The main safety measure was adverse events.

30 rding to the Common Terminology Criteria for Adverse Events.

31 mal peak flow, antibiotic use, or nonserious adverse events.

32 ce of death, sudden death, and other cardiac adverse events.

33 us adverse events or discontinuations due to adverse events.

34 fety assessments included treatment-emergent adverse events.

35 crease in cardiovascular and cerebrovascular adverse events.

36 up discontinued the trial regimen because of adverse events.

37 ade 1-2); none discontinued treatment due to adverse events.

38 dies reported low rates of death and serious adverse events (0% to 1.25%) in nontransported patients

39 3%] of 223 vs 141 [64%] of 219) or a serious adverse event (11 [5%] of 223 vs 63 [29%] of 219).

40 Numbers of discontinuations related to adverse events (11 [1%] of 763 patients in the study gro

41 primary outcomes were treatment failure and adverse events 14 days after diagnosis.

42 ab emtansine plus pertuzumab had a grade 3-4 adverse event (29 [13%] of 223 vs 141 [64%] of 219) or a

43 17 serious adverse events (3%) were reported during the study: one

44 patients in the control group) and grade 3-4 adverse events (52 [7%] patients vs 31 [8%] patients) we

45 n the atazanavir group reported drug-related adverse events (83 [33%] vs 121 [49%]) or adverse events

46 n the olaparib group had a treatment-related adverse event (acute myeloid leukaemia) with an outcome

47 At least one emergent adverse event (AE) was recorded for 79/190 (41x6%) in th

48 lpatasvir-voxilaprevir therapy because of an adverse event (AE).

49 Overall, 71% of patients suffered an adverse event (AE); the majority of these were grades 1

50 Before ASCT, adverse events (AEs) occurred in 98% of patients, mostly

51 Treatment related adverse events (AEs) were experienced by 18 patients (75

52 The most common nonhematologic adverse events (AEs) were nausea (75%), fatigue (70%), a

53 Daily temperatures and adverse events (AEs) were recorded days 1 to 42 postvacc

54 Safety measures included adverse events (AEs), clinical laboratory tests, vital s

55 Grade >/=3 adverse events (AEs; >5%) included anemia, pneumonia, an

56 ney, leading to dose-limiting toxicities and adverse events affecting quality of life.

57 the placebo group; the most frequent serious adverse events (affecting >/=2% of patients) were elevat

58 The most common treatment-related adverse events among the 54 patients were hypercholester

59 The primary outcome was the incidence of adverse events among vaccine and placebo recipients thro

60 hic angiography and strongly associated with adverse events among women.

61 in dementia patients, the increased risk of adverse events and cognitive decline, there is an unmet

62 Due to the increasing rate of adverse events and hospitals facing financial penalties

63 personalize trajectories, thereby decreasing adverse events and optimizing cancer treatment.

64 al, body region scanned, type, dose, related adverse events and route of administration of sedatives

65 ATION: Despite an increase in haematological adverse events and second primary malignancies, lenalido

66 bamazepine-CR had serious treatment-emergent adverse events, and 47 (11%) and 69 (16%), respectively,

67 nths, hemodialysis- and chemotherapy-related adverse events, and death.

68 , including time to death, the occurrence of adverse events, and intensive care unit resource use.

69 atment-related unsolicited grade 3 or higher adverse events, and no new-onset chronic illnesses.

70 t metastasis-free survival, quality of life, adverse events, and safety.

71 r 92% of the 48 hours cooling period without adverse events, and was lower than the controls (34.35 d

72 after surgery; delirium; mortality; serious adverse events; and neurocognition.

73 Secondary objectives included assessment of adverse events, antidrug antibodies, and factors contrib

74 Treatment-related adverse events (any grade) prompted treatment discontinu

75 Adverse events are defined with Valve Academic Research

76 150 mug had at least one treatment-emergent adverse event, as did all three (100%) placebo recipient

77 of blood-product use, infection, and serious adverse events, as well as 28-day mortality, did not dif

78 trointestinal disorders were the most common adverse event associated with drug discontinuation or do

79 370 patients died from non-treatment-related adverse events associated with death, and one patient di

80 e surgical risk, with a different pattern of adverse events associated with each procedure.

81 However, the adverse events associated with smoking limit its clinica

82 m 2004 to 2009 and subsequent post-discharge adverse events at 1 year.

83 No other serious adverse events attributable to angiotensin II were repor

84 Adverse events attributable to PHS cost an additional $6

85 53 patients had a serious treatment-related adverse event: autoimmune disorder (two [13%]), lower ab

86 arge differences in risk of systemic serious adverse events between these two anti-VEGF drugs; i.e.,

87 There was no difference in the occurrence of adverse events between treatment arms.

88 26 (39%) of 44 patients had grade 3 adverse events, but no grade 4 events were reported.

89 n in-hospital AKI and risk of post-discharge adverse events by AKIN stage.

90 Adverse events caused the premature study discontinuatio

91 secondary objectives included evaluation of adverse events, changes in sexual quality of life using

92 Safety endpoints were adverse events, clinical laboratory values, vital signs,

93 s included safety (rate of treatment-related adverse events), CLSS grade, and Global Aesthetic Improv

94 (42%) patients in the benralizumab group had adverse events compared with 49 (47%) in the placebo gro

95 Adverse events comprised CVD death, myocardial infarctio

96 tudy drug, which were grade 2 neurocognitive adverse events comprising slowed speech and mentation an

97 Institute's Common Terminology Criteria for Adverse Events (CTCAE) via tablet computers at 5 success

98 pneumonia, five [5%]); four deaths were from adverse events deemed treatment-related (pneumonia, two

99 Rates of grade 3-4 adverse events did not differ among regimens (P = .37).

100 Incidence of treatment-emergent adverse events did not differ between extended-pulsed fi

101 Overall and serious adverse events did not differ between the flecainide and

102 The overall rate of serious adverse events did not differ between treatment groups,

103 er, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the

104 The annual frequency of adverse events did not occur more frequently with cumula

105 Incidence of treatment-related adverse events did not seem to be associated with dose a

106 One serious adverse event during deferred treatment (interstitial ne

107 Adverse events (eg, lethargy, diarrhoea, rash, and nause

108 There were no adverse events either immediately or at 2-week follow-up

109 Nine patients died from adverse events; five of these deaths were judged to be r

110 the transition from desired drug effects to adverse events following administration of either therap

111 Serious adverse events for all patients included anastomotic lea

112 To investigate adverse event free admissions as a potential, patient-ce

113 Major cardiovascular adverse events-free survival was worse in patients with

114 Frequent severe adverse events (>4% difference from placebo) were diarrh

115 12 patients reported serious adverse events; haemolysis and pyrexia were the most com

116 regate of hemocompatibility-related clinical adverse events (HRAEs) between the 2 LVAS.

117 art failure, or CVD death), and (ii) serious adverse events (hypotension, syncope, electrolyte abnorm

118 outcome mainly relies on the declaration of adverse events, identification of their predictors, self

119 from mechanical ventilation is viewed as an adverse event in ICUs.

120 The most common serious adverse event in the active surveillance group was myoca

121 3 patients) was the most frequently reported adverse event in the alternative ACT group.

122 Common adverse events in patients treated at the MTD (n = 57) i

123 febrile neutropenia (27 [17%] of 155 serious adverse events in patients who received doxorubicin and

124 ived doxorubicin and 15 [12%] of 130 serious adverse events in patients who received gemcitabine and

125 We recorded adverse events in ten (34%) of 29 patients given twice-w

126 Ocular adverse events in the aflibercept group included 4 parti

127 than 10 mm Hg greater than baseline; ocular adverse events in the bevacizumab group included 1 parti

128 The most frequently reported adverse events in the brexanolone group were dizziness (

129 most common in both groups (six [27%] of 22 adverse events in the ketamine group vs seven [54%] of 1

130 domisation; the most common grade 3 or worse adverse events in the remaining 16 patients evaluable fo

131 ry endpoint was the number and percentage of adverse events in the treatment period in an intention-t

132 the placebo group, or in the risk of serious adverse events (in 8.3% in the vaccine group and in 9.1%

133 Adverse event incidences in the 24-week placebo-controll

134 Exercise-related adverse events included musculoskeletal injuries.

135 A variety of dermatologic immune-related adverse events including maculopapular eruption, licheno

136 ed antitoxin (n = 193), 23 (12%) reported an adverse event, including rash, fever, serum sickness, an

137 nd recognising, responding to and disclosing adverse events, including errors and near misses.

138 e and unpredictable number of immune-related adverse events (IRAE).

139 Adverse events led to treatment discontinuation for 13 p

140 23 (22%) patients died because of adverse events (mainly from sepsis, eight [8%]; and pneu

141 Seven (44%) of 16 patients had serious adverse events, most of which were related to the underl

142 even patients (61%) experienced drug-related adverse events (mostly grade 1-2); none discontinued tre

143 Frequency of adverse events, mostly mild self-limited joint and back

144 Most discontinuations were due to adverse events-mostly gastrointestinal with semaglutide,

145 and one patient died from treatment-related adverse events (myositis in addition to grade 3 thyroidi

146 Two (1%) of 166 patients had serious adverse events; neither were considered related to study

147 There were no treatment-related serious adverse events, no treatment-related unsolicited grade 3

148 %) patients had 11 grade 3 treatment-related adverse events; no single event occurred in more than on

149 management group reported treatment-emergent adverse events; no treatment-related deaths occurred.

150 No serious adverse event occurred in more than one participant and

151 In these patients, no adverse event occurred when clinical pathways were corre

152 Treatment-emergent serious adverse events occurred in 103 (7%) women in the neratin

153 Drug-related adverse events occurred in 130 (24%) of 531 participants

154 Serious adverse events occurred in 2 patients in the IFN group,

155 Grade 3 or worse treatment-related adverse events occurred in 21 (8%) of 249 patients, the

156 Adverse events occurred in 21 of 23 (91%) control patien

157 Minor adverse events occurred in 22% of patients in the contro

158 Grade 3 or worse treatment-related adverse events occurred in 23 (13%) of 184 patients; the

159 Drug-related serious adverse events occurred in 28 (38%) of 74 patients.

160 Five serious adverse events occurred in 4 cases (15%), including pulm

161 Grade 3 to 5 adverse events occurred in 47% of the patients in the co

162 Adverse events occurred in 51 (48%) of CGM participants

163 s, and only grade 1 (mild) local or systemic adverse events occurred in both groups.

164 Eight serious adverse events occurred in each group.

165 Most adverse events occurred in the first day after vaccinati

166 een treatment groups, although some specific adverse events occurred more often in the intensive grou

167 Two unexpected serious adverse events occurred, both for the first patient enro

168 No adverse events occurred.

169 Serious adverse events occurring in 5% or more of patients were

170 Serious adverse events occurring in more than two patients inclu

171 ociated with a higher risk of the well-known adverse events of fever, rash, and convulsions within th

172 The most common adverse events of grade 3 or higher during treatment wer

173 Adverse events of grade 3 or higher were reported in 87%

174 The most common adverse events of grade 3 or worse severity were anaemia

175 Trial withdrawals and adverse events of rash, dizziness, and dental discolorat

176 Six (3%) patients had 11 serious adverse events: one (2%) patient in the placebo group, t

177 range, 20-30 mo), no patients had a serious adverse event or relapse of vasculitis.

178 There were no serious adverse events or discontinuations due to adverse events

179 significant differences in local or systemic adverse events or laboratory abnormalities between the P

180 recurrence or new breast cancer, intolerable adverse events, or consent withdrawal occurred.

181 occurred because of adverse events, serious adverse events, or deaths in patients who received lanad

182 Adverse events owing to PHS are costly and represent a q

183 tional cohort study, we compared time to any adverse event (primary outcome); serious or nonserious e

184 the placebo groups were reportedly suspected adverse events, probably related to the vaccine; however

185 mes included abnormal laboratory results and adverse events proximate to MRA initiation.

186 Rate of adverse events, quality of life, and patient satisfactio

187 ondary end points included anatomic patency, adverse event rate, and return to operating room within

188 for multiple comparisons was used to compare adverse event rates among the products.

189 th an increase in overall treatment-emergent adverse event rates or neurocognitive events, although c

190 t treatments were not associated with higher adverse event rates than placebo.

191 Adverse event rates with family reporting (28.7 per 1000

192 s, representing 111 (39%) of all 285 serious adverse events recorded, were febrile neutropenia (27 [1

193 Serious adverse events (regardless of relation to study treatmen

194 Adverse events related to study drug were less common wi

195 The most common adverse events reported in the re-treatment ACT group we

196 The most common grade 3-4 haematological adverse events reported, irrespective of attribution, we

197 Of the 88 deaths (grade 5 adverse events) reported during the study (50 patients [

198 The Food and Drug Administration Adverse Event Reporting System (FAERS) remains the prima

199 The three most common serious adverse events, representing 111 (39%) of all 285 seriou

200 [11.1%]) or placebo (32 of 255 [12.5%]); all adverse events resolved without sequelae.

201 secondary outcomes were incidence of CDI and adverse events, respectively.

202 icant difference in the incidence of serious adverse events (RR: 1.02; 95% CI: 0.94 to 1.09) or renal

203 nd 3-, 6-, and 12-months for safety (serious adverse events [SAE]), and efficacy endpoints: ejection

204 ontraindications were predefined and serious adverse events (SAEs) were reported to ethics committees

205 arcoma group) had treatment-emergent serious adverse events (SAEs), five of whom had immune-related S

206 powered to identify risk factors for serious adverse events (SAEs), thereby limiting their influence

207 Physical adverse events (self-reported breathing problems, sleep

208 No discontinuations occurred because of adverse events, serious adverse events, or deaths in pat

209 son for discontinuation was gastrointestinal adverse events such as nausea.

210 is needed to optimize its dosing to minimize adverse events, such as peripheral neuropathy.

211 nts with T2MI had higher rates of subsequent adverse events than those without T2MI (per 100 person-y

212 (20%) of 265 assigned placebo had a serious adverse event that was judged by the investigator to be

213 ed adverse events (83 [33%] vs 121 [49%]) or adverse events that led to discontinuation (ten [4%] vs

214 (16%), respectively, had treatment-emergent adverse events that led to withdrawal.

215 nd headache were the only treatment-emergent adverse events that occurred in at least 5% of participa

216 Adverse events that occurred more frequently in the cann

217 The most common serious adverse events that occurred through week 24 were anaemi

218 d placebo reported at least one on-treatment adverse event, the most common of which were headache (i

219 Fifteen patients experienced grade 3 to 4 adverse events; the most common were fluid retention and

220 ched for studies in which rates of immediate adverse events to GBCAs were reported.

221 One serious adverse event (transient atrial fibrillation) occurred i

222 RCE was well tolerated with no adverse events.Twice daily RCE intake over 1 y potently

223 One adverse event unrelated to study devices occurred during

224 ed in phase 3 trials), the most common local adverse events versus placebo within the first 14 days w

225 The only possible DSM265-related adverse event was a moderate transient elevation in seru

226 The most common adverse event was an elevated creatine kinase concentrat

227 The most common drug-related adverse event was headache.

228 , whereas the most common non-haematological adverse event was hypokalaemia (25 [17%] of 147 vs 22 [1

229 The most common adverse event was neutropenia (80 [26%] of 312 patients

230 The most common adverse event was pain related to surgical incision or p

231 The proportion of severe adverse events was 0.6% in the e-POCT arm compared with

232 al ACC volume, and the magnitude of lifetime adverse events was inversely associated with left hippoc

233 tients who discontinued treatment because of adverse events was low (range, 0%-1%).

234 Incidence and severity of adverse events was mostly similar between groups except

235 Incidence of adverse events was similar for alirocumab versus control

236 Incidence of adverse events was similar in all groups (43 [88%] of 49

237 The incidence of adverse events was similar in all three groups.

238 The number of adverse events was similar regardless of immunisation st

239 to high-frequency hearing loss, an expected adverse event, was documented in all participants.

240 kers and plasma cardiac injury biomarkers in adverse events, we conducted a multicenter prospective c

241 The most common serious adverse events were anaemia (eight [4%]), upper gastroin

242 Adverse events were attributable to 23 (5%) deaths in th

243 Adverse events were common with medications but not with

244 The most common grade 3 adverse events were decreased lymphocyte (n=3) and decre

245 The most common grade 3-4 adverse events were decreased neutrophil count (210 [37%

246 Adverse events were defined as fatal or nonfatal aortic

247 he most frequently reported grade 3 or worse adverse events were diarrhoea (103 [21%] of 488 patients

248 Serious adverse events were experienced by 35 (18%) patients in

249 Grade 3/4 adverse events were experienced by 43% of patients.

250 The most common adverse events were fatigue (seven participants [27%]),

251 Treatment-related adverse events were generally grade 1 or 2 in severity.

252 Adverse events were generally mild (</= grade 2), with d

253 Thirteen serious adverse events were identified among recipients of HRV,

254 The most common adverse events were infective pulmonary exacerbations, c

255 The most common isatuximab-related adverse events were infusion-associated reactions (IARs)

256 Data on adverse events were limited, but suggested an increased

257 All the adverse events were mild or moderate in severity.

258 Adverse events were more frequent with clindamycin (58 o

259 Adverse events were more frequent with tofacitinib than

260 and placebo (n=260) groups, the most common adverse events were nasopharyngitis (38 [14%] vs 36 [12%

261 in the 30 enrolled patients the most common adverse events were nasopharyngitis (n=7; 23%) and fall

262 The most comment grade 3-4 adverse events were neutropenia (n=2 [5%]), hypertension

263 Adverse events were not assessed.

264 Deaths due to adverse events were observed in 27 (12%) patients in the

265 Fewer grade 3 and 4 treatment-related adverse events were observed in patients on nivolumab (1

266 Adverse events were rarely reported.

267 Adverse events were recorded at baseline, 3 hours, and 2

268 No severe adverse events were recorded.

269 Adverse events were reported as expected and were simila

270 Grade 3 to 4 treatment-related adverse events were reported in 38.3% and 61.7% of the p

271 Serious adverse events were reported in 56 (58%) eltrombopag-tre

272 Serious adverse events were reported in 64 (22%) of 288 patients

273 No grade 3 or 4 adverse events were reported in either study.

274 11 serious adverse events were reported in seven (25%) patients and

275 Three serious adverse events were reported, all in patients in the ada

276 No adverse events were reported.

277 No severe vaccine-related adverse events were reported.

278 Most adverse events were respiratory, and in some patients it

279 Treatment-related serious adverse events were similar between groups (13 [11%] in

280 Adverse events were similar between the subgroups.

281 Discontinuation due to adverse events were similar in both arms (6% lapatinib a

282 The rates of renal adverse events were similar in the liraglutide group and

283 The most common adverse events were skin reactions occurring in 49 (48%)

284 Patient characteristics and adverse events were studied and compared between patient

285 Psychiatric adverse events were the most common in both groups (six

286 2) The most common grade 3 to 4 drug-related adverse events were thrombocytopenia (47%), neutropenia

287 The most frequently observed grade 3 and 4 adverse events were transaminase increases (40% alanine

288 ons with obstruction as a severe and serious adverse event, which was considered as unrelated to stud

289 Safety was assessed on the basis of adverse events, which were graded according to the Commo

290 cant between-group difference in the risk of adverse events, which were reported in 68.7% of the infa

291 The most common grade 3-4 adverse events with a suspected association with long-ac

292 patients had treatment-related grade 3 or 4 adverse events with atezolizumab (90 [15%] of 609 patien

293 Common adverse events with bevacizumab and octreotide included

294 Adverse events with liraglutide affected mainly the gast

295 Pigmentation was the most common minor adverse event, with a 3.53% treated-vein pigmentation le

296 Serious adverse events within 12 months after injection were see

297 e incidence of study product-related serious adverse events within 180 days, grade 3 solicited or uns

298 ic illnesses within 180 days and unsolicited adverse events within 28 days, all analysed by intention

299 n 180 days, grade 3 solicited or unsolicited adverse events within 28 days, and solicited injection s

300 he procedure, and rates of serious and minor adverse events within 30 days of the procedure.